Zydus Healthcare launches NDDS product Nudoxa

MUMBAI: Zydus Cadila has introduced an NDDS product for treatment of various types of cancer, which is stable and long lasting with reduced toxicity and side effects. Nudoxa is a patented product in India and South Africa, and patents have also been filed in EU, US, Japan and other countries.

Doxorubiein, the first generation drug and gave a new lease of life to cancer patients with its ability to combat aggressive and malignant tumours. This DNA-interacting drug, however, was discovered to cause life-threatening side effects in the form of cardiac abnormalities.

A new variant liposomal doxorubiein Nudoxa with its unique drug delivery system is a breakthrough in cancer therapy as it offers the benefits of Pegylaled-liposomal doxorubiein without its major side effects like the Hand Foot syndrome. Marketed by Zydus Biogen, Nudoxa is manufactured by Zydus-BSV Pharma, the joint venture company of Zydus Cadila and Bharat Serums and Vaccines.

Nudoxa is being used as a chemotherapy drug to treat various cancers, particularly, breast cancer - second most common type of cancer, ovarian cancer - the fifth-leading cause of cancer death in women, and AIDS-related Kaposi sarcoma which develops in people who are infected with the human immunodeficiency virus (HIV).